Literature DB >> 1370047

Towards third-generation whooping cough vaccines.

R Rappuoli1, M Pizza, A Podda, M T De Magistris, L Nencioni.   

Abstract

To date, the most significant use of recombinant-DNA technologies has been to hyperproduce natural molecules that are difficult to obtain in large quantities by conventional methods. However, genetic manipulation can also be an efficient way to modify the properties of natural molecules in order to make them more suitable for human use. In the development of third-generation whooping cough vaccines, recombinant-DNA methods were used to remove the enzymatic activity of pertussis toxin in order to obtain a new molecule which is devoid of toxicity, and can be used for safer vaccination against this disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1370047     DOI: 10.1016/0167-7799(91)90076-t

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  3 in total

1.  Characterization of recombinant tetanus toxin derivatives suitable for vaccine development.

Authors:  D Figueiredo; C Turcotte; G Frankel; Y Li; O Dolly; G Wilkin; D Marriott; N Fairweather; G Dougan
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

2.  Detoxification of the Helicobacter pylori cytotoxin.

Authors:  R Manetti; P Massari; M Marchetti; C Magagnoli; S Nuti; P Lupetti; P Ghiara; R Rappuoli; J L Telford
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

3.  Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.

Authors:  E J Ryan; E McNeela; G A Murphy; H Stewart; D O'hagan; M Pizza; R Rappuoli; K H Mills
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.